Marizyme Stock Performance
| MRZM Stock | USD 0.05 0.01 25.00% |
Marizyme holds a performance score of 7 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -3.54, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Marizyme are expected to decrease by larger amounts. On the other hand, during market turmoil, Marizyme is expected to outperform it. Use Marizyme jensen alpha, potential upside, as well as the relationship between the Potential Upside and daily balance of power , to analyze future returns on Marizyme.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Marizyme are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Marizyme displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.9 M |
Marizyme |
Marizyme Relative Risk vs. Return Landscape
If you would invest 4.00 in Marizyme on September 3, 2024 and sell it today you would earn a total of 1.00 from holding Marizyme or generate 25.0% return on investment over 90 days. Marizyme is currently generating 1.9234% in daily expected returns and assumes 19.6661% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Marizyme, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Marizyme Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Marizyme's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Marizyme, and traders can use it to determine the average amount a Marizyme's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0978
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | MRZM | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 19.67 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.92 actual daily | 38 62% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Marizyme is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Marizyme by adding it to a well-diversified portfolio.
Marizyme Fundamentals Growth
Marizyme OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Marizyme, and Marizyme fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Marizyme OTC Stock performance.
| Return On Equity | -0.5 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (180.85) % | |||
| Current Valuation | 17.35 M | |||
| Shares Outstanding | 10.13 M | |||
| Price To Book | 0.37 X | |||
| Price To Sales | 133.06 X | |||
| Revenue | 210.28 K | |||
| EBITDA | (10.83 M) | |||
| Cash And Equivalents | 2.04 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 495.32 K | |||
| Debt To Equity | 0.07 % | |||
| Book Value Per Share | 1.00 X | |||
| Cash Flow From Operations | (5.79 M) | |||
| Earnings Per Share | (0.39) X | |||
| Total Asset | 66 M | |||
About Marizyme Performance
By examining Marizyme's fundamental ratios, stakeholders can obtain critical insights into Marizyme's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Marizyme is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida. Marizyme operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 11 people.Things to note about Marizyme performance evaluation
Checking the ongoing alerts about Marizyme for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Marizyme help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Marizyme is way too risky over 90 days horizon | |
| Marizyme has some characteristics of a very speculative penny stock | |
| Marizyme appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 210.28 K. Net Loss for the year was (11 M) with profit before overhead, payroll, taxes, and interest of 129.93 K. | |
| Marizyme currently holds about 2.04 M in cash with (5.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05. |
- Analyzing Marizyme's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Marizyme's stock is overvalued or undervalued compared to its peers.
- Examining Marizyme's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Marizyme's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Marizyme's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Marizyme's otc stock. These opinions can provide insight into Marizyme's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Marizyme OTC Stock
Marizyme financial ratios help investors to determine whether Marizyme OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Marizyme with respect to the benefits of owning Marizyme security.